Chai Discovery raised $400 million in a Series C, tripling the startup’s valuation versus its prior round and fueling its AI-generated drug discovery platform. The funding highlights continued investor appetite for molecule design companies leveraging large-scale generative models. The round adds to Chai’s accelerating financing cadence since earlier funding in 2026 and positions the company to scale model capabilities and expand commercial partnerships. Earlier disclosures point to use cases spanning major pharma workflows, with Chai’s models supporting target-to-lead candidate generation. For biotech operators, the strategic significance is speed-to-candidate: AI molecule generators are increasingly used to narrow chemical search spaces before wet-lab validation. However, repeatability and manufacturability remain decisive as programs progress from computational hits to developable series. Industry scrutiny will focus on evidence of translating model output into differentiated biological profiles across multiple targets and on whether the company can maintain model quality as datasets and retraining scale.